IPO

Accretion Pharmaceuticals Limited IPO

NSE SME

Listed On: May 21, 2025 at ₹ 79.0

₹ 242400 /2400 Shares
*Min Investment

Check Allotment

14 May, 2025

Open Date

16 May, 2025

Close Date

19 May, 2025

Allotment Date

21 May, 2025

Listing Date
Expected Premium
+ ₹0

*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.

Expected Premium
+ ₹0
Accretion Pharmaceuticals IPO Issue Details
  • Issue Price ₹96-101 per equity share
  • Face Value ₹10 Per Equity Share
  • Total Issue Size 29,46,000 shares(aggregating up to ₹29.75 crore)
  • Fresh Share 29,46,000 shares(aggregating up to ₹29.75 crore)
  • Listing at NSE SME
  • List Price 79.0
  • Listing Date 2025-05-21
  • Lead Manager Jawa Capital Services Private Limited
  • Registrar Kfin Technologies Limited
Market Lot Size

Investors can bid for a minimum of 1200 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

ApplicationLotsSharesAmount
Retail (min)11200₹1,21,200
Retail(max)11200₹1,21,200
NII (min) 22,400₹2,42,400
Accretion Pharmaceuticals IPO Documents
DRHP
RHP
Accretion Pharmaceuticals IPO Details


Accretion Pharmaceuticals Limited IPO is an SME IPO, priced at ₹96-101 per equity share. The equity shares have a face value of ₹10 Per Equity Share each and will be listed on the NSE SME platform. The IPO comprises a total issue of 29,46,000 equity shares, aggregating up to ₹29.75 crores..

The IPO bidding window is open from May 14, 2025 to May 16, 2025. The allotment is expected to be finalized on May 19, 2025, and the tentative listing date is May 21, 2025.

The minimum lot size for Retail investors is 1200 shares, with a minimum investment of ₹1,21,200. For HNIs, the minimum application size is 2 lots , amounting to ₹ 2,42,400.

Jawa Capital Services Private Limited is acting as the lead manager to the issue. The registrar of the IPO is Kfin Technologies Limited, and Gretex Share Broking Private Limited will act as the market maker for this issue.

Read More
Accretion Pharmaceuticals IPO Subscription Analysis And Details
Retail
10.54x
Total
7.67x
As onQIB / NIIRetailTotal
Shares Offered / Reserved1,41,600 / 12,22,80012,22,80025,87,200
Day 1 14-05-25 06:00 PM
0.00 / 0.51 x1.86 x1.12 x
Day 2 15-04-25 06:00 PM
0.75 / 0.92 x4.01 x2.37 x
Day 3 16-05-25 06:00 PM
12.14 / 4.28 x10.54 x7.67 x
Total No of Applications
11,625
Accretion Pharmaceuticals Valuations
EPS Pre IPO ₹4.74/-
EPS Post IPO ₹6.28/-
P/E Pre IPO 21.29
P/E Post IPO 16.08
ROE 72.47%
ROCE 36.73%
Debt/Equity 2.52
RoNW 72.47%
PAT Margin 11.51
Price to Book Value 7.55
Accretion Pharmaceuticals Company Financials
In Crs.
In Cr.
31-Dec-2431-Mar-2431-Mar-2331-Mar-22
Assets39.9927.0520.5817.74
Revenue35.7533.9429.5322.58
Profit After Tax5.243.880.100.08
Net Worth13.585.353.843.08
Reserves & Surplus5.411.350.000.00
Total Borrowing13.7913.488.477.61
About Accretion Pharmaceuticals Company

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical firm that produces and markets tablets, capsules, and other health care products.

The company provides contract manufacturing services as well. The Company produces and sells Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).The company is also certified by ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005, demonstrating its commitment towards quality and environmental management systems.

The manufacturing facility of the company is situated in Ahmedabad, Sanand, Gujarat.The company has spread its wings globally, representing itself in over 20 countries, with locations in Africa, Southeast Asia, as well as the Middle East.

Product Portfolio and Services:
Tablets and Capsules – Encompassing antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal drugs.
Oral Liquids and Syrups – For respiratory, pediatric, and gastrointestinal treatments.
External Preparations – Such as medicated lotions, gels, ointments, and dusting powders for skin treatment and dermatological therapy.
Ayurvedic and Herbal Products – Emphasizing natural wellness remedies for immunity, digestion, and overall health.

As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.

Read More
Accretion Pharmaceuticals - Promoter(s)

Mr. Mayur Popatlal Sojitra

Mr. Harshad Nanubhai Rathod

Mr. Vivek Ashok Kumar Patel

Mr. Hardik Mukundbhai Prajapati

Pre Issue Share Holding : 100%

Post Issue Share Holding : 73.48%

Accretion Pharmaceuticals IPO - Issue Objectives
1

Capital expenditure towards purchase of new equipment/ machineries, etc.

2

Capital expenditure towards upgradation of existing manufacturing facility

3

Repayment/prepayme nt of certain borrowings availed by the Company

4

Funding working capital requirements

5

General Corporate Purpose

Contact Details

Accretion Pharmaceuticals

29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat,India, 382213

+91-97148 82929

compliance@accretionpharma.com

https://accretionpharma.com/

Registrar Contact Details

Kfin Technologies Limited

04067162222, 04079611000

apl.ipo@kfintech.com

https://kosmic.kfintech.com/ipostatus/